About
Enterin
Leadership
Board of Directors
Advisors
Science
Gut-Brain Axis
Parkinson’s Disease
Metabolic Diseases
CLINICAL TRIALS
KARMET- Phase 2b
RASMET – Phase 2a
Research
Lead Programs
Pipeline
Scientific Publications
News
Contact
Contact
Careers
Loading...
Enterin is aiming to become the first company
in the world to develop a novel drug that
repairs the dysfunctional
gut-brain axis
in patients with neurodegenerative disease.
Learn More
In preclinical models of Parkinson’s Disease,
ENT-01 displaces
α-synuclein aggregates
and restores normal signaling between the gut and the brain.
Learn More
Our lead molecule, ENT-01,
has recently met its primary endpoint
in a Phase 2b study for patients with Parkinson's Disease.
Learn More
Our clinical data indicates that
repair of the gut-brain axis is able to
significantly improve
quality of life
by influencing multiple non-motor symptoms that affect patients with Parkinson’s Disease and other neurodegenerative conditions.
Learn More
Watch an interview with one of Enterin’s founders,
Dr. Michael Zasloff, discussing a new hope
against Parkinson’s,
autism and other neurodegenerative diseases.
WATCH THE VIDEO
